Refocussing therapeutic strategies for cardiac arrhythmias: Defining viable molecular targets to restore cardiac ion flux

Expert Opinion on Therapeutic Patents

Volumn 18, Issue 1, 2008, Pages 1-19

  George, Christopher H ^a   Barberini Jammaers, Steven R ^a   Muller, Carsten T ^b  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Anti arrhythmics; Cardiac arrhythmias; Devices; Drugs; Fibrillation; Innovation

Indexed keywords

4 [3 (4 BENZYL 1 PIPERIDINYL)PROPIONYL] 2,3,4,5 TETRAHYDRO 7 METHOXY 1,4 BENZOTHIAZEPINE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; AMIODARONE; ANTIARRHYTHMIC AGENT; ARATAC; ASTEMIZOLE; AZIMILIDE; BENZOXAZINONE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CARBOSTYRIL DERIVATIVE; CARRIER PROTEIN; CISAPRIDE; DIGOXIN; DOFETILIDE; DRONEDARONE; GAP JUNCTION PROTEIN; ICP CALSTAN 100; KB 130015; MULTAQ; NORPHENAZONE; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL KV1.5; PROTEIN KINASE (CALCIUM,CALMODULIN) II; ROTIGAPTIDE; RYANODINE RECEPTOR; SODIUM CHANNEL BLOCKING AGENT; SOTALOL; TERFENADINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERNAKALANT;

ARTIFICIAL HEART PACEMAKER; CELL COMPARTMENTALIZATION; CLINICAL TRIAL; DEFIBRILLATION; DISEASE ASSOCIATION; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RETENTION; DRUG SAFETY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; EYE DISEASE; HEART ARRHYTHMIA; HEART MUSCLE CELL; HEART SURGERY; HUMAN; INDIVIDUALIZATION; ION TRANSPORT; LIVER DYSFUNCTION; LUNG FIBROSIS; MEDICAL LITERATURE; MITOCHONDRION; MORBIDITY; MORTALITY; PATIENT CARE; PREVALENCE; QT PROLONGATION; RADIOFREQUENCY ABLATION; REVIEW; RISK ASSESSMENT; SARCOPLASMIC RETICULUM; SOCIAL STATUS; THYROID DISEASE; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT;

EID: 39749193540     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.18.1.1     Document Type: Review

References (158)

1. Health statistics and health information systems. Available from: http://www.who.int/healthinfo/statistics/bodgbddeathdalyestimates.xls
2. Lopshire JC, Zipes DP. Sudden cardiac death: better understanding of risks, mechanisms, and treatment. Circulation 2006;114:1134-6
3. Zipes DP, Camm JA, Borgreffe M, et al. ACC/AHA/ESC 2006 Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - executive summary. J Am Coll Cardiol 2006;48:e247-346
4. Priori SG. Inherited arrhythmogenic diseases: the complexity beyond monogenic disorders. Circ Res 2004;94:140-5
5. Zipes DP, Wellens HJJ. Sudden cardiac death. Circulation 1998;98:2334-51
6. Bers DM. Excitation-contraction coupling and contractile force (Ed.), Kluwer Academic Publishers, 2001;452
7. Patentscope®. Available from: http://www.wipo.int/patentscope/en/
8. Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov 2006;5:1034-49
9. Trybulski EJ. Anti-arrhythmic agents. Exp Opin Ther Patents 1997;7:457-9
10. Anker SD, Jankowska EA, Okonko DO. Therapeutic patents for chronic heart failure: a review of patent applications from 1996 to 2002. Exp Opin Ther Patents 2004;14:639-54
11. Ashcroft FM. From molecule to malady. Nature 2006;440:440-7
12. George CH, Jundi H, Thomas NL, Fry DL, Lai FA. Ryanodine receptors and ventricular arrhythmias: emerging trends in mutations, mechanisms and therapies. J Mol Cell Cardiol 2007;42:34-50
13. Marban E. Cardiac channelopathies. Nature 2002;415:213-8
14. 2+ release channel dysfunction. Curr Pharm Des 2007;13:3195-211
15. Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 2006;113:305-15
16. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patient receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-4
17. Cast Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-33
18. Siebels J, Cappato R, Ruppel R, Schneider MAE, Kuck KH. Preliminery results of the Cardiac Arrest Study Hambury (CASH). Am J Cardiol 1993;72:109F-113F
19. Waldo AL, Camm AJ, Deruyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12
20. Burr ML, Ashfield-Watt PAL, Dunstan FDJ, et al. Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr 2003;57:193-200
21. Avid Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83
22. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37
23. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996;335:1933-40
24. Strickberger SA, Hummel JD, Bartlett TG, et al. Amiodarone versus implantable cardiovercer-defibrillator: randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia-AMIOVERT. J Am Coll Cardiol 2003;41:1707-12
25. Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004;350:2151-8
26. Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarcrion. N Engl J Med 2004;351:2481-8
27. Bigger JT. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 1997;337:1569-75
28. Medtronic, Inc. WO2007065123 (2007)
29. Kaikkonen KS, Kortelainen ML, Linna E, Huikuri H. Family history and the risk of sudden cardiac death as a manifestation of an acute coronary event. Circulation 2006;114:1462-7
30. Dekker LRC, Bezzina CR, Henriques JPS, et al. Familial sudden death is an important risk factor for primary ventricular fibrillation. Circulation 2006;114:1140-5
31. Cast Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12
32. European Society of Cardiology Task Force. The Sicilian Gambit - a new approach to the classification of anti-arrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circ Res 1991;84:1831-51
33. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-74
34. Schwartz PJ, Camm AJ, Frangin G, et al. Does amiodarone reduce sudden death and cardiac mortality after myocardial infarction? The European Myocardial Infarct Amiodarone Trial (EMIAT). Eur Heart J 1994;15:620-4
35. Cairns JA, Connolly SJ, Roberts RL, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-82
36. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82
37. Boutitie F, Boissel JP, Connolly SJ, et al. Amiodarone interaction with beta-blockers: analysis of the merged EMIAT and CAMIAT databases. Circulation 1999;99:2268-75
38. Pfizer, Inc. US5158964 (1992)
39. Kato Bio. WO03009839 (2003)
40. 2+] in ventricular myocytes. J Pharmacol Exp Ther 2006; 316:162-8
41. ISP Investments, Inc. WO03040120 (2003)
42. Gautier P, Guillemare E, Marion A, et al. Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. J Cardiovasc Electrophysiol 2003;41:191-202
43. Wegener FT, Ehrlich JR, Hohnloser SH. Dronedarone: an emerging agent with rhythm- and rate-controlling effects. J Cardiovasc Electrophysiol 2006;17:S17-20
44. Procter & Gamble Co. US6083945 (2000)
45. Procter & Gamble Co. US2007021395 (2007)
46. Dorian P, Borggrefe M, Al-Khalidi HR, et al. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Circulation 2004;110:3646-54
47. Astrazeneca. WO2007069986 (2007)
48. Astrazeneca. WO9931100 (1999)
49. Cardiome Pharmaceutial Corporation. US2007197632 (2007)
50. Bristol-Myers Squibb. US2007142333 (2007)
51. Merck & Co., Inc. WO200750348 (2007)
52. Isner JM. Myocardial gene therapy. Nature 2002;415:234-9
53. Hoshijima M. Gene therapy targeted at calcium handling as an approach to the treatment of heart failure. Pharmacol Ther 2005;105:211-8
54. Johns Hopkins University. WO02087419 (2002)
55. Children's Hospital of Philadelphia. US2004087528 (2004)
56. Johns Hopkins University. US2007048284 (2007)
57. Kashiwakura Y, Cho HC, Barth AS, Azene E, Marban E. Gene transfer of a synthetic pacemaker channel into the heart: a novel strategy for biological pacing. Circulation 2006;114:1682-6
58. Sasano T, McDonald AD, Kikuchi K, Donahue JK. Molecular ablation of ventricular tachycardia after myocardial infarction. Nat Med 2006;12:1256-8
59. Merillat J, Lakarta EG, Hano O, Guarnieri T. Role of calcium and the calcium channel in the initiation and maintenance of ventricular fibrillation. Circ Res 1990;67:1115-23
60. Kafiluddi R, Kennedy RH, Seifen E. Effects of ryanodine on inotropic and arrhythmogenic actions of cardiotonic steroids. Eur J Pharmacol 1986;131:273-8
61. Kusuoka H, Jacobus WE, Marban E. Calcium oscillations in digitalis-induced ventricular fibrillation: pathogenic role and metabolic consequences in isolated ferret hearts. Circ Res 1988;62:609-19
62. Zealand Pharmaceuticals. WO2005061437 (2005)
63. Zealand Pharmaceuticals. WO03063891 (2003)
64. Eloff BC, Gilat E, Wan X, Rosenbaum DS. Pharmacological modulation of cardiac gap junctions to enhance cardiac contraction. Circulation 2003;108:3157-63
65. Hennan JK, Swillo RE, Morgan GE, et al. Rotigaptide (ZP123) prevents spontaneous ventricular arrhythmias and reduces infarct size during myocardial ischemia/reperfusion injury in open-chest dogs. J Pharmacol Exp Ther 2006;317:236-43
66. Haugan K, Olsen KB, Hartvig L, et al. The antiarrhythmic peptide analog ZP123 prevents atrial conduction slowing during metabolic stress. J Cardiovasc Pharmacol 2005;16:537-45
67. Clarke TC, Thomas D, Petersen JS, Evans WH, Martin PE. The antiarrhythmic peptide rotigaptide (ZP123) increases gap junction intercellutar communication in cardiac myocyres and HeLa cells expressing connexin 43. Br J Pharmacol 2006;147:486-95
68. Zealand Pharmaceuticals. WO2004048400 (2004)
69. Zealand Pharmaceuticals, Wyeth Corporation. WO2007078990 (2007)
70. Dhein S. Pharmacology of gap junctions in the cardiovascular system. Cardiovasc Res 2004;62:287-98
71. Medicure International, Inc. WO2007059631(2007)
72. 7 receptor induces the release of epoxyeicosatrienoic acids. Br J Pharmacol 2007;151:1033-40
73. Otsuka Pharmaceutical Co. WO9406427 (1994)
74. Syntex, Inc. WO9403425 (1994)
75. University of Texas, Myogen, Inc. WO2005049084 (2005)
76. Harks EGA, Camina JP, Peters PHJ, et al. Besides affecting intracellular calcium signaling, 2-APB reversibly blocks gap junctional coupling in confluent monolayers, thereby allowing the measurement of single-cell membrane currents in undissociated cells. FASEB J 2003; DOI:10.1096/ fj.02-0786fje
77. Bai D, Del Corsso C, Srinivas M, Spray DC. Block of specific gap junction channel subtypes by 2-aminoethoxydiphenyl borate (2-APB). J Pharmacol Exp Ther 2006;319:1452-8
78. Tao L, Harris AL. 2-Aminoethoxydiphenyl borate directly inhibits channels composed of connexin 26 and/or connexin 32. Mol Pharmacol 2007;71:570-9
79. Huang YJ, Maruyama Y, Dvoryanchikov G, et al. The role of pannexin 1 hemichannels in ATP release and cell-cell communcation in mouse taste buds. Proc Natl Acad Sci USA 2007;104:6436-41
80. Locovei S, Bao L, Dahl G. Pannexin 1 in erythrocytes: function without a gap. Proc Natl Acad Sci USA 2006;103:7655-9
81. Goodenough DA, Paul DL. Beyond the gap: functions of unpaired connexon hemichannels. Nat Rev Mol Cell Biol 2003;4:1-10
82. Evans WH, De Vuyst E, Leybaert L. The gap junction cellular internet: connexin hemichannels enter the signalling limelight. Biochem J 2006;397:1-14
83. 2+ leak in heart failure: mere observation or functional relevance? Cardiovasc Res 2008; In Press. Doi: 10.1093/cvr/cvm1006
84. Anderson ME. Multiple downstream proarrhythmic targets for calmodulin kinase II: moving beyond an ion channel-centric focus. Cardiovasc Res 2007;73:657-66
85. Maier LS, Bers DM. Calcium, calmodulin and calcium-calmodulin kinase II: heartbeat to heartbeat and beyond. J Mol Cell Cardiol 2002;34:919-39
86. Kaneko N. New 1,4-benzothiazepine derivative, K201, demonstrates cardioprotective effects against sudden cardiac death and intracellular calcium blocking action. Drug Develop Res 1994;33:429-38
87. Japan Tobacco Co. WO9212148 (1992)
88. Columbia University. WO2006101497 (2006)
89. Columbia University. WO2005094457 (2005)
90. 2+ release in heart failure. Cardiovasc Res 2000;48:323-31
91. Kohno M, Yano M, Kobayashi S, et al. A new cardioprotective agent, JTV519, improves defective channel gating of ryanodine receptor in heart failure. Am J Physiol Heart Circ Physiol 2003;284:H1035-42
92. Wehrens XHT, Lehnart SE, Reiken SR, et al. Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin 2. Science 2004;304:292-6
93. Yano M, Yamamoto T, Ikeda Y, Matsuzaki M. Mechanisms of disease: ryanodine receptor defects in heart failure and fatal arrhythmia. Nat Clin Prac Cardiovasc Med 2006;3:43-52
94. Columbia University. US2007173482 (2007)
95. Columbia University. WO2005037195 (2005)
96. Columbia University. WO2004080283 (2004)
97. Lisy O, Burnett JC. New cardioprotective agent K201 is natriuretic and glomerular filtration rate enhancing. Circulation 2006;113:246-51
98. 2+ overload in isolated rat hearts. Cardiovasc Drugs Ther 2000;14:489-95
99. Tse HF, Lam WF. JTV-519 Japan tobacco. Curr Opin Investig Drugs 2001;2:936-9
100. Gun T, Zhang T, Mestril R, Bers DM. Ca/Calmodulin-dependent protein kinase II phosphorylation of ryanodine receptor does affect calcium sparks in mouse ventricular myocytes. Circ Res 2006;99:398-406
101. 2+/Calmodulin-dependent protein kinase II: the dominating twin of protein kinase A. Circ Res 2006;99:333-5
102. Khoo MSC, Li J, Singh MV, et al. Death, cardiac dysfunction, and arrhythmias are increased by calmodulin kinase II in calcineurin cardiomyopathy. Circulation 2006;114:1352-9
103. Leland Stanford Junior University. US2003134777 (2003)
104. Vanderbilt University. US2004266675 (2004)
105. University of Alabama at Birmingham. US2003153951 (2003)
106. + currents. Circ Res 2006;99:1092-9
107. 2+ release in cat ventricular myocytes. J Physiol 2006; 577:281-93
108. Zima AV, Blatter LA. Redox regulation of cardiac calcium channels and transporters. Cardiovasc Res 2006;71:310-21
109. Ventura-Clapier R, Garnier A, Veksler V. Energy metabolism in heart failure. J Physiol 2004;555:1-13
110. Gazmuri RJ, Ayoub IM, Hoffner E, Kolarova JD. Successful ventricular defibrillation by the selective sodium-hydrogen exchanger isoform-1 inhibitor cariporide. Circulation 2001;104:234-9
111. Ayoub IM, Kolarova J, Yi Z, et al. Sodium-hydrogen exchange inhibition during ventricular fibrillation: beneficial effects on ischemic contracture, action potential duration, reperfusion arrhythmias, myocardial function, and resuscitibility. Circulation 2003;107:1804-9
112. + exchange inhibitor, on ventricular arrhythmias in animal hearts. Eur J Pharmacol 1996;317:309-16
113. Landmesser U, Drexler H. Chronic heart failure: an overview of conventional treatment versus novel approaches. Nat Clin Prac Cardiovasc Med 2005;2:628-38
114. 2+ leak induced by oxidative stress. Circ J 2006;70:777-86
115. Baltogiannis GG, Tsalikakis DG, Mitsi AC, et al. Endothelin receptor A blockade decreases ventricular arrhythmias after myocardial infarction in rats. Cardiovasc Res 2005;67:647-54
116. Crockett TR, Scott GA, McGowan NW, Kane KA, Wainwright CL. Anti-arrhythmic and electrophysiological effects of the endothelin receptor antagonists, BQ-123 and PD161721. Eur J Pharmacol 2001;432:71-7
117. Burrell KM, Molenaar P, Dawson PJ, Kaumann AJ. Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: blockade with SB209670. J Pharmacol Exp Ther 2000;292:449-59
118. Ishizawa M, Mizushige K, Noma T, et al. An antioxidant treatment potentially protects myocardial energy metabolism by regulating uncoupling protein 2 expression in a chronic beta-adrenergic stimulation rat model. Life Sci 2006;78:2974-82
119. Freudenberger RS, Schwarz RPJ, Brown J, et al. Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III-IV congestive heart failure. Expert Opin Investig Drugs 2004;13:1509-16
120. Cardiome Pharma Corp. press release: Cardiome Reports Clinical Results From OPT-CHF Study. Available from: http://cardiome.com/wordpress/?p=252
121. Mitsubishi Pharmaceutical Co. WO03080583 (2003)
122. Mitsubishi Pharmaceutical Co. WO2006016707 (2006)
123. Edaravone Acute Infarction Study Group. Effect of a novel free scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003;15:222-9
124. Yano M, Okuda S, Oda T, et al. Correction of defective interdomain interaction within ryanodine receptor by antioxidant is a new therapeutic strategy against heart failure. Circulation 2005;112:3633-43
125. Yagi H, Horinaka S, Matsuoka H. Edaravone prevented deteriorated cardiac function after myocardial ishemia-reperfusion via inhibiting lipid peroxidation in rat. J Cardiovasc Electrophysiol 2005;46:46-51
126. Yamawaki M, Sasaki N, Shimoyama M, et al. Protective effect of edaravone against hypoxia-reoxygenation injury in rabbit cardiomyocytes. Br J Pharmacol 2004;142:618-26
127. Neuromed Pharmaceutical Ltd. WO200145709 (2007)
128. Takeda Pharmaceutical Co. WO2007077961 (2007)
129. Neuromed Technologies, Inc. WO2007071035 (2001)
130. Johns Hopkins University. WO2006138487 (2006)
131. Johns Hopkins University. US2002091144 (2006)
132. Tsujimoto Y, Shimizu S. Another way to die: autophagic programmed cell death. Cell Death Differ 2005;12:1528-34
133. Faust Pharmaceuticals. WO2007071379 (2007)
134. Ellenbogen KA, O'Neill G, Prystowsky EN, et al. Trial to evaluate the management of paroxysmal supraventricular tachycardia during an electrophysiology study with tecadenoson. Circulation 2005;111:3202-8
135. Peterman C, Sanoski CA. Tecadenoson: a novel, selective A1 adenosine receptor antagonist. Cardiol Rev 2005;13:315-21
136. Kyowa Hakko Kogyci KK. EP0619316 (1994)
137. Janssen Pharmaceutica. WO2007081995 (2007)
138. Lim M, Honisett S, Sparkes CD, et al. Differential effect of urotensin II on vascular cone in normal subjects and patients with chronic heart failure. Circulation 2004;109:1212-4
139. Sagami Chemical Research: JP10139664 (1998)
140. Sagami Chemical Research. WO9420092 (1994)
141. Massachusetts General Hospital. US5760081 (1998)
142. Albert CM, Campos H, Stampfer MJ, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002;346:1113-8
143. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8
144. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intake on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;ii:757-61
145. Marchioli R, Barzi F, Bomba E, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarcation: time-course analysis of the results of the Gruppo Italiano per to Studio delta Sopravvivenza nll'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002;105:1897-903
146. 2+ exchange currents in HEK293t cells. Biochem Biophys Res Commun 2004;321:116-23
147. Leaf A, Kang JX, Xiao YF, Billman GE. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanisms of prevention of arrhythmias by n-3 fish oils. Circulation 2003;107:2646-52
148. Guizy M, Arias C, David M, Gonzalez T, Valenzuela C. Omega-3 and omega-6 polyunsaturated fatty acids block HERG channels. Am J Physiol Cell Physiol 2005;289:C1251-60
149. Avestha Gengraine Technologies. WO2007068997 (2007)
150. Dsm NV. US2004059142 (2004)
151. Resolvyx Pharmaceuticals. US2004044050 (2004)
152. Suntory Ltd. WO2006019186 (2006)
153. Burr ML, Dunstan FDJ, George CH. Is fish oil good or bad for heart disease? Two trials with apparently conflicting results. J Membrane Biol 2005;206:155-63
154. University of Leipzig: WO2007073730 (2007)
155. Ali MS, Ibrahim SA, Jalil S, Choudhary MI. Ursolic acid: a potent inhibitor of superoxides produced in the cellular system. Phytother Res 2007;21:558-61
156. Chong CR, Sullivan DJ. New uses for old drugs. Nature 2007;448:645-6
157. Cohen FJ. Macro trends in pharmaceutical innovation. Nat Rev Drug Discov 2005;4:78-84
158. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3:673-83